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Specificity and Application of the
Lantibiotic Protease NisP
Manuel Montalbán-López †‡, Jingjing Deng ‡, Auke J. van Heel and Oscar P. Kuipers*
Department Molecular Genetics, University of Groningen, Groningen, Netherlands
Lantibiotics are ribosomally produced and posttranslationally modified peptides
containing several lanthionine residues. They exhibit substantial antimicrobial activity
against Gram-positive bacteria, including relevant pathogens. The production of the
model lantibiotic nisin minimally requires the expression of the modification and export
machinery. The last step during nisin maturation is the cleavage of the leader peptide.
This liberates the active compound and is catalyzed by the cell wall-anchored protease
NisP. Here, we report the production and purification of a soluble variant of NisP. This has
enabled us to study its specificity and test its suitability for biotechnological applications.
The ability of soluble NisP to cleave leaders from various substrates was tested with
two sets of nisin variants. The first set was designed to investigate the influence of
amino acid variations in the leader peptide or variations around the cleavage site. The
second set was designed to study the influence of the lanthionine ring topology on
the proteolytic efficiency. We show that the substrate promiscuity is higher than has
previously been suggested. Our results demonstrate the importance of the arginine
residue at the end of the leader peptide and the importance of lanthionine rings in the
substrate for specific cleavage. Collectively, these data indicate that NisP is a suitable
protease for the activation of diverse heterologously expressed lantibiotics, which is
required to release active antimicrobial compounds.
Keywords: lantibiotic, nisin, bacteriocin, Lactococcus lactis, NisP, leader peptidase, subtilisin-like protease
INTRODUCTION
Lanthipeptides are posttranslationally modified peptides that contain dehydrated amino acids and
(methyl)lanthionine residues (Knerr and van der Donk, 2012; Arnison et al., 2013). Lantibiotics
are those lanthipeptides that have significant antimicrobial activity, namely lanthipeptide classes I
and II. Some lantibiotics show activity against clinically relevant bacteria in a concentration range
comparable to antibiotics in use. Moreover, they can target multidrug resistant bacteria (Mota-
Meira et al., 2000; Piper et al., 2009). The production of the model lantibiotic nisin (belonging to
the class I lanthipeptides) by Lactococcus lactis requires the coordinated expression of 11 genes
(Lubelski et al., 2008). Prenisin is produced as a linear prepeptide that undergoes dehydration and
cyclization in a directional and alternating way (Lubelski et al., 2009) and is subsequently exported
by a dedicated transporter (NisT). Outside the cell, the protease NisP cleaves off the leader peptide
releasing mature nisin (Kuipers et al., 1993). In this process, the leader peptide of nisin serves as a
recognition motif for the modification enzymes and the transporter and keeps the fully modified
prenisin inactive until it is removed (Kuipers et al., 1993; van der Meer et al., 1993; Oman and van
der Donk, 2010; Khusainov et al., 2011, 2013; Plat et al., 2011, 2013; Khusainov and Kuipers, 2012;
Abts et al., 2013; Yang and van der Donk, 2013).
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The proteases involved in the maturation of lanthipeptides
recognize different cleavage sites. The type I lanthipeptide
proteases, generally referred to as LanP, are subtilisin-like serine
proteases. They can be secreted to the extracellular medium, like
EpiP (Geissler et al., 1996), or remain in the cytoplasm, like
PepP (Meyer et al., 1995), or be exported and bound to the
cell wall, like NisP. In the maturation of subtilin, no specific
protease has been found and the processing takes place outside
the cell probably by diverse serine proteases (Corvey et al., 2003).
The first lantibiotic protease with a resolved 3D structure, EpiP
from Staphylococcus aureus, an analog of NisP, has been reported
(Kuhn et al., 2014; Xu et al., 2014). On the other hand, in type
II lanthipeptides, the protease domain is fused to the transporter
and this protein cleaves behind a double glycine motif (Knerr and
van der Donk, 2012). In type III lanthipeptides, the cleavage is
not so specific and is mediated by a prolyl oligopeptidase (Völler
et al., 2013).
The modification enzymes of the nisin biosynthesis gene
cluster have been used to produce potent and stable variants
of clinically relevant peptides, providing extensive information
regarding the promiscuity of the modification machinery
(NisBC) and the transporter (NisT) (Kuipers et al., 2004;
Kluskens et al., 2005, 2009; Rink et al., 2005, 2007a,b; Moll et al.,
2010; Bosma et al., 2011; van Heel et al., 2016). The production
of modified prelantibiotics allows to obviate the requirement for
immunity and can achieve higher yields, although it requires
a later activation by cleavage of the leader peptide (Valsesia
et al., 2007; Majchrzykiewicz et al., 2010; Montalbán-López et al.,
2017). Moreover, NisRK expressed in diverse strains provides
a widely used inducible protein expression system for Gram-
positive bacteria (De Ruyter et al., 1996; Eichenbaum et al., 1998;
Mierau and Kleerebezem, 2005).
The promiscuity of NisBTC and the development of an
efficient production system for the modification and export of
modified peptides enabled the production of putative lantibiotics
from diverse bacteria in L. lactis (Majchrzykiewicz et al., 2010;
van Heel et al., 2016). Moreover, this production system can
be extended with additional enzyme modules (i.e., additional
modification enzymes found in lantibiotic gene clusters) (van
Heel et al., 2013) or with non-canonical amino acids (Zhou et al.,
2016; Baumann et al., 2017; Zambaldo et al., 2017) that increase
the repertoire of unusual amino acids that can be incorporated
in vivo in peptides. These findings highlight the large potential
of using Synthetic Biology principles in the production of novel
lanthipeptides (for a review see Montalbán-López et al., 2012,
2017 and references therein). The versatility of the NisBTC
system allows for the production of a large number of putative
prelantibiotics. Thus, a protease capable of releasing the active
lantibiotic during growth of the producer strain is indispensable
for using high-throughput screening systems on novel peptides.
Additionally, the production of modified prelantibiotics can
achieve higher yields because no immunity is required being
the only drawback the necessity of a suitable leader peptidase
(Valsesia et al., 2007). Therefore, we tested the suitability of
diverse commercial proteases for the cleavage of the leader
peptide of nisin after maturation in various growth conditions.
We compared their activity with that of the lantibiotic protease
NisP, especially in view of the importance of the variable residues
present behind the cleavage site, to establish the potential of NisP
for various biotechnological applications.
The nisin protease, NisP, is produced and exported to the
outside of the cell, where it is anchored to the peptidoglycan via
a sortase-catalyzed coupling and performs its function, although
a fraction of the protease escapes anchoring (van der Meer
et al., 1993; Siezen et al., 1995; Xu et al., 2014). It contains a
typical N-terminal secretion signal, a protease domain, a self-
cleavage C-terminal sequence and a sortase recognition sequence
(Figure 1A). The maturation of NisP involves the release of the
signal peptide and part of the prepeptide, likely by self-cleavage
of the N-terminal sequence (van der Meer et al., 1993), as has
been shown for an EpiP-analog (Kuhn et al., 2014). Although
the role of NisP in the production of nisin is crucial, little is
known about the specificity of the protease or the recognition
sites present in prenisin that allow for the binding and cleavage of
the leader peptide, although recently the influence of lanthionine
rings on processing specificity has been reported (Lagedroste
et al., 2017). Moreover, the fact that NisP is attached to the
cell wall has prevented a detailed study of the specificity of
NisP. Here, we present a systematic study of an engineered
soluble variant of the lantibiotic protease NisP. This work will
greatly facilitate the efficient production and activation of a wide
variety of active lantibiotics with a cost-effectively produced
protease.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
The bacterial strains and vectors used in this work are listed
in Table 1. Lactococcal strains were grown in M17 (Oxoid),
supplemented with 0.5% glucose (GM-17) at 30◦C for genetic
manipulation or in the same conditions, but in MEM for peptide
production (Rink et al., 2005). Escherichia coli and Micrococcus
flavus strains were grown in LB at 37◦C, while shaking at 250
rpm. When appropriate, erythromycin and/or chloramphenicol
(Sigma-Aldrich) were added at a final concentration of 5µg/ml.
Kanamycin (Sigma-Aldrich) was used at a final concentration of
20µg/ml.
Construction of Expression Vectors
Cloning steps were performed following standard protocols
(Sambrook et al., 2001). The preparation of competent L. lactis
cells and transformation were carried out according to Holo and
Nes (1995). Restriction endonucleases and ligase were used as
recommended by the provider (Thermo Fisher Scientific).
For the cloning of nisP variants, the gene was amplified from
the genome of L. lactis NZ9700 using primers nisPbsphfwd and
nisP8KXbarev or nisPbsphfwd and nisP8KSacIr for the addition
of a 8-mer poly-lysine tag, nisPbsphfwd and nisP8HXbarev
or nisPbsphfwd and nisP8HSacIr for the addition of a 8-mer
poly-histidine tag, or nisPbsphfwd and solNisPcontrol for the
production of an untagged soluble NisP (Supplementary Table 1).
The amplification was performed using Phusion Polymerase
(Thermo Fisher Scientific) following the provider’s instructions.
After amplification, the DNA was purified using the PCR
Frontiers in Microbiology | www.frontiersin.org 2 February 2018 | Volume 9 | Article 160
Montalbán-López et al. Specificity of NisP
FIGURE 1 | (A) Schematic view of wild-type NisP, NisP mutants generated in this work and other LanPs. 8H represents the 8-histidine tag, 8K represents the 8-lysine
tag, and nt denotes no tag added. The dotted line around the signal peptide in LanP indicates that this part is not present in all LanP proteases. (B) Alignment of
diverse type I lantibiotic peptides. The F(D/N)LD motif and the Pro-2 are highly conserved. The cleavage site is indicated with an equal to sign (=).
cleaning kit (Roche) and digested with BspHI and XbaI or BspHI
and SacI and ligated in pNZ8048 digested with NcoI and either
XbaI or SacI. Similarly, the fragment was inserted into pET28b
digested with NcoI and either SpeI or SacI. The ligation mix was
transformed into L. lactis NZ9000 or E. coli Rosetta Blue DE3.
The nucleotide sequence of each gene was checked by sequencing
with the primers listed in Supplementary Table 1.
For the construction of pNZE3nisA-CAAAA-ASPR, the nisin
CAAAA coding gene (last 4 Cys replaced by Ala) was synthesized
by GeneArt and cloned into pNZE3-empty (van Heel et al.,
2013) as a BglII-HindIII fragment encoding the PnisA promoter
and nisin-CAAAA. For the construction of pNZE3nisA-Cysless-
ASPR, Nisin Cys-less was amplified from pNZE3-Cys-less
(Khusainov and Kuipers, 2013) using the primers pNZE3Emf
and C-lessH6-less, digested with BglII and HindIII, and cloned
into pNZE3-empty cut with the same enzymes. pNZE3nisA-
C7A-VSLR was produced by round PCR of pNZnisA-E3 using
the primers NisPC7A-rev and NisPC7A-fwd. pNZE3nisA-C7A-
ASPR was produced by round PCR of pNZE3nisA-C7A-VSLR
using the primers NisPC7A-rev and NisPC7A-ASPR-fwd The
equivalent genes in which the end of the leader peptide was
mutated from ASPR to VSLR were generated by round-PCR
of each of the plasmids mentioned above with the primers
nisVSLRfwd and nisVSLRrev.
The nisin variants with a mutation in the first two amino acids
of the core peptide were produced by round PCR of pNZnisA-
E3 using phosphorylated P-for as a forward primer in all cases
and P-IK-Rev, P-KT-Rev, P-WT-Rev, P-DT-Rev or P-IV-Rev for
Nisin A-T2K, Nisin A-I1K, Nisin A-I1W, Nisin A-I1D and Nisin
A-T2V mutants, respectively.
Gene Expression and Product Purification
An overnight culture of L. lactis NZ9000 grown in GM17
with the desired plasmid(s) was diluted 50-times in preheated
MEM and grown until an OD 600 nm of 0.4–0.6. At this
moment, the culture was induced with 5 ng/ml of nisin (Sigma-
Aldrich). Cells were harvested after 3 h of induction and the
supernatants containing the protein of interest were further
purified.
Trichloroacetic acid (TCA) precipitation was carried out
according to Sambrook et al. (2001). The purification of nisin
and its mutants in higher amounts was performed according to
described protocols (Lubelski et al., 2009). When higher purity
was required, the fractions collected were applied to a spherical
C18 versaflash column (Supelco) previously equilibrated in 0.1%
trifluoroacetic acid (TFA). The column was washed in three
steps with 3 volumes of 33, 66, and 100% organic solvent (2:1
isopropanol:acetonitrile 0.1% TFA). After this step, the peptides
were concentrated by freeze-drying.
For the purification of soluble truncated NisP, the producer
cells were grown and induced at an OD 600 nm of 0.4–0.6
with either 5 ng/ml nisin or 1mM IPTG depending on the
producer strain being L. lactis NZ9000 or E. coli Rosetta Blue
DE3, respectively. The cells were separated after 3 h induction
by centrifugation at 6,000 rpm for 10min at 4◦C. The his-tagged
variant NisP-8H was purified by affinity chromatography using a
Ni-NTA fast flow resin (Qiagen). Briefly, the cell-free supernatant
of L. lactis strains or the cell-lysate of E. coli strains was passed
through a column previously equilibrated with binding buffer
(20mM phosphate buffer 0.5M NaCl pH 8.0). The column
was washed with 50mM phosphate buffer 0.5M NaCl 20mM
imidazole pH 8.0. NisP-8H was eluted from the column using
50mMphosphate buffer 0.5MNaCl 250mM imidazole. NisP-8K
was purified by cationic exchange chromatography using a Fast-
flow SP-sepharose (GEHealthcare). The columnwas equilibrated
with 5 column volumes of 20mM phosphate buffer pH 6.5. The
pH of the supernatant was adjusted to pH 6.5 and then passed
through the column. After washing with 5 column volumes of
20mM phosphate pH 6.5 0.5M NaCl, the attached protein was
eluted with 20mM phosphate pH 6.5 1.5M NaCl.
The presence of NisP and its variants in elution fractions
was assessed by checking the ability to activate prenisin in
antimicrobial assays and/or by SDS-PAGE according to Laemmli
(1970).
Frontiers in Microbiology | www.frontiersin.org 3 February 2018 | Volume 9 | Article 160
Montalbán-López et al. Specificity of NisP
TABLE 1 | Strains and vectors used in this work.
Strain Characteristics References
Lactococcus lactis NZ9000 nisRK::pepN Kuipers et al., 1997
Lactococcus lactis NZ9700 Nisin producer Kuipers et al., 1993
Micrococcus flavus B423 Sensitive strain NIZO Food Research
Escherichia coli Rosetta Blue DE3 Expression host Novagen
Plasmid Characteristics References
pET28b Vector with the IPTG inducible PT7. Km
R Novagen
pNZ8048 CmR PnisA De Ruyter et al., 1996
pNZE3-empty EryR van Heel et al., 2013
pIL3BTC CmR PnisA-nisBTC Rink et al., 2005
pNZnisA-E3 EryR PnisA-nisA Kuipers et al., 2004
pNZE3-Cys-less C-terminal His-tagged Nisin (C7A C11A C18A C25A C27A) mutant. EryR Khusainov and Kuipers, 2013
pIL253 EryR Simon and Chopin, 1988
pNGnisTP CmR PnisA-nisTP Kuipers et al., 2004
pNZnisP-8H PnisA-nisP with 8 histidines tag after the subtilisin-like domain. Cm
R This work
pNZnisP-8K PnisA-nisP with 8 lysines tag after the subtilisin-like domain. Cm
R This work
pNZnisP-sol PnisA-nisP with no tag fused after the subtilisin-like domain. Cm
R This work
pNZnisPsl-8H PnisA-nisP sortase-less with 8 histidines tag. Cm
R This work
pNZnisPsl-8K PnisA-nisP sortase-less with 8 lysines tag. Cm
R This work
pETNisP-sol PT7-nisP with no tag fused after the subtilisin-like domain. Km
R This work
pETNisP-8H PT7-nisP with 8 lysines tag after the subtilisin-like domain. Km
R This work
pETnisP-8K PT7-nisP with 8 lysines tag fused after the subtilisin-like domain. Km
R This work
pNZE3nisA-C7A-ASPR Nisin C7A mutant. EryR This work
pNZE3nisA-Cysless-ASPR Nisin (C7A C11A C18A C25A C27A) mutant lacking all cysteines. EryR This work
pNZE3nisA-CAAAA-ASPR Nisin (C11A C18A C25A C27A) mutant retaining only the first cysteine in the prepeptide.
EryR
This work
pNZE3nis-ringAless-ASPR Nisin (T2V S3A S5A C7A) mutant, EryR This work
pNZE3nisA-VSLR Nisin (A-4V P-2L) mutant containing a VSLR instead of the typical ASPR sequence in the
leader, EryR
This work
pNZE3nisA-C7A-VSLR Nisin (A-4V P-2L C7A) mutant with a VSLR NisP cleavage site, EryR This work
pNZE3nisA-Cysless-VSLR Nisin (A-4V P-2L C7A C11A C18A C25A C27A) mutant lacking all cysteines and with a
VSLR NisP site, EryR
This work
pNZE3nisA-CAAAA-VSLR Nisin (A-4V P-2L C11A C18A C25A C27A) mutant retaining only the first cysteine in the
prepeptide and with a VSLR NisP site, EryR
This work
pNZE3nisA-ringAless-VSLR Nisin (A-4V P-2L T2V S3A S5A C7A) mutant with a VSLR NisP site, EryR This work
pNZE3nisA-I1D Nisin I1D mutant, EryR This work
pNZE3nisA-I1W Nisin I1W mutant, EryR This work
pNZE3nisA-I1K Nisin I1K mutant, EryR This work
pNZE3nisA-T2K Nisin T2K mutant, EryR This work
pNZE3nisA-T2V Nisin T2V mutant, EryR This work
pNZE3-DDDK NisP cleavage site ASPR replaced by DDDK, EryR Plat et al., 2011
pNZE3-DDDDK NisP cleavage site GASPR replaced by DDDDK, EryR Plat et al., 2011
pNZE3-AFNLD Nisin D-19A mutant, EryR Plat et al., 2011
pNZE3-DANLD Nisin F-18A mutant, EryR Plat et al., 2011
pNZE3-DFALD Nisin N-17A mutant, EryR Plat et al., 2011
pNZE3-DFNAD Nisin L-16A mutant, EryR Plat et al., 2011
pNZE3-DFNLA Nisin D-15A mutant, EryR Plat et al., 2011
pNZE3-nis-V8 Nisin Z R-1E mutant, EryR This work
pNZE3-nis-Fx Nisin Z (A-4I S-3E P-2G) mutant with IEGR replacing the ASPR NisP cleavage site, EryR This work
pNZE3-nis-Thr Nisin Z (S-3V) mutant with AVPR replacing the ASPR NisP cleavage site, EryR This work
pNZE-nis1(23-34) Nisin 1(23-34) deletion mutant, EryR Rink et al., 2007b
pNZE3-1765 nisin leader peptide fused to the leaderless part encoded by spr1765, EryR Majchrzykiewicz et al., 2010
pNZE3-1766 nisin leader peptide fused to the leaderless part encoded by spr1766, EryR Majchrzykiewicz et al., 2010
CmR, chloramphenicol resistance; EryR, erythromycin resistance.
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Proteolysis of Nisin and Nisin Mutants
Using NisP
Lyophilized nisin or its mutants were solubilized using a 0.05%
acetic acid solution. Different buffers were prepared: 1MHEPES,
1MNaCl, 1MHEPES 50mMCaCl2, 1MHEPES 50mMMgCl2,
1M MES, 1M MES 50mM CaCl2. In all cases, the pH was
adjusted to 6.5 and mixed with each sample and then diluted
10 times. Additionally, 1M Tris 50mM CaCl2 pH 6.0 was
tested. The pH was measured after mixing and corrected if
necessary.
Alternatively, supernatants containing nisin mutant peptides
produced after induction were divided into two fractions; one in
which the pH was adjusted to 6.0 and the other one where the pH
was the actual fermentation pH. They were incubated overnight
at 37◦C with or without His-tagged purified NisP at a ratio of
1000:1. After the incubation, the supernatants were precipitated
using TCA and resuspended in 1/20 volume 0.05% acetic acid.
For the mutants that were produced in lower amounts, larger
volumes were induced and the peptides were purified by cationic
exchange chromatography as described before and separated by
reverse phase chromatography using a Jupiter 4µm Proteo 90
Å 250 × 4.6mm C12 analytical column (Phenomenex). The
column was equilibrated in 20% organic solvent (acetonitrile
0.1% TFA) before the sample injection. It was washed for 5min
before applying a linear gradient from 20 to 50% organic solvent




Mass spectrometry analysis of the samples was performed by
matrix-assisted laser desorption/ionization (MALDI) time-of-
flight (ToF) in an ABI Voyager DE Pro (Applied Biosystems)
operating in linear mode as previously described using external
calibration (van Heel et al., 2013). Briefly, 1 µl sample was
spotted, dried and washed with 5 µL Milli-Q water, on the
target. Next, 1 µl of α-cyano-4-hydroxycinnamic acid 5 mg/ml
(Sigma-Aldrich) was spotted on the sample.
Activity Test
Activity tests were performed by well-diffusion assay as indicated
by van Heel et al. (2013). L. lactis NZ9000 transformed with
the appropriate plasmids or Micrococcus flavus were used as
sensor strains as specified in each figure. The cleavage of
nisin by NisP after SDS-PAGE was monitored washing the gel
according to Bhunia et al. (1987) and covering with an overlay
of GM17 soft agar inoculated with NZ9000 (pIL3BTC pNZnisA-
E3) induced with 1 ng/ml nisin. The overlay was incubated
for 16 h, after which the presence of inhibition zones was
evaluated.
Enzyme Kinetic Assays
In order to investigate the substrate specificity and kinetic
parameters of NisP, a set of mutants of P4-P1 was created.
We used wild-type prenisin (ASPR), nis-Peng (VSLR), nis-
Thrombin (AVPR), and nis-Factor Xa (IEGR) as substrates. The
concentration of NisP was determined by the BCA assay with
bovine serum albumin as standard. The conditions of cleavage
reaction were optimized with 100mM Tris buffer containing
5mM CaCl2 (pH 6.0). The reaction was stopped at the indicated
times adding TFA to a final concentration of 1%. The reaction was
performed in 100 µl with 6.5 ng/ml NisP at 37◦C. 1% TFA was
added to terminate the reaction at 5 different time points (5, 15,
30, 45, and 60min). All the samples were analyzed by analytical
RP-HPLC as indicated before (Mu et al., 2015) and measuring
the absorbance at 205 nm. For each substrate concentration, the
initial velocity was calculated on the basis of the peak area of
released nisin vs. time. The kinetic parameters were determined
by fitting the calculated enzyme activities at different substrate
concentrations (ranging from 1 to 25µM) to a linear regression
curve on Lineweaver–Burk double reciprocal plot (Lineweaver
and Burk, 1934).
RESULTS
Cloning and Expression of a Soluble NisP
Variant
The fact that NisP is a cell wall anchored protease has hindered a
thorough characterization and assessment of its biotechnological
properties. In a first attempt to produce soluble NisP, we
designed primers that hybridize partially to the sequence of NisP
immediately upstream of the sortase recognition sequence in
the C-terminus of NisP (LPVTG). We designed the primers
nisP8KXbarev and NisP8HXbarev, which add a tail of 8-Lys or
8-His residues, respectively. These tags facilitate the purification
of the protease and can also serve for the immobilization on
different materials for high-throughput applications.
The supernatants of the strains NZ9000 (pNZnisPsl-8H)
and NZ9000 (pNZnisPsl-8K) were tested for the presence of
protease activity after 3 h of induction with nisin. In each
case, 5 µl of the supernatant was mixed with 50 µl of
prenisin obtained by TCA precipitation of induced NZ9000
(pIL3BTC pNZnisA-E3). Positive controls using trypsin or the
supernatant of induced NZ9000 (pNGnisTP) and a negative
control containing only prenisin were used. The presence of an
appropriate protease in the mix will release active nisin, thus we
can monitor the activity of NisP by measuring the antimicrobial
activity against the sensitive strain Micrococcus flavus. We could
observe antimicrobial activity only in the positive controls, thus
indicating that the variant NisP protease, if produced, is not
active (data not shown).
In a second approach, we attempted to reduce the size of
NisP, while keeping the active subtilisin-like domain intact. An
alignment comparing different LanP proteases shows that NisP
has a hydrophobic helix after the protease domain which is
not present in other intracellular proteases (Velásquez et al.,
2011). Thus, we decided to express a NisP variant that lacks
the sortase recognition sequence and this motif. Similarly, we
amplified the gene adding a C-terminal tag of either 8 histidines,
or 8 lysines or no tag. We repeated the activity test with the
supernatants of induced L. lactisNZ9000 (pNZnisP-sol), NZ9000
(pNZnisP-8H) and NZ9000 (pNZnisP-8K) (Figure 2A). In this
case we were able to detect antimicrobial activity for all the
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FIGURE 2 | Activity of engineered NisP variants. (A) Activation of prenisin with supernatants of induced L. lactis NZ9000 transformed with pNZnisP-sol (1),
pNZnisP-8H (2), pNZnisP-8K (3), or pNGnisTP (4), using M. flavus as an indicator strain. (B) Activity of NisP heterologously produced in E. coli Rosetta Blue DE3 using
the prenisin producing strain L. lactis NZ9000 (pNZnisA-E3 pIL3BTC) both as producer and as sensitive strain. 20 µl of cell lysate of E. coli (pET28b) (1), E. coli
(pETNisP-sol) (2) or E. coli (pETNisP-8H) (3) were added to the wells. 1 µl of NisP-8H purified from L. lactis NZ9000 (pNZnisP-8H) was used as a positive control (4).
(C) SDS-PAGE of NisP-8H purified by affinity chromatography from L. lactis NZ9000 (pNZnisP-8H). Wells 1-6 contain 15 µl of each 2 ml-fraction collected. (D)
Activation of prenisin by NisP-8H purified from L. lactis NZ9000 (pNZnisP-8H) using L. lactis NZ9000 (pNZ8048 pIL253) as a sensitive strain. Wells 1-6 correspond to a
mix of 50 µl of supernatants of induced L. lactis NZ9000 (pNZnisA-E3 pIL3BTC) and 2 µl of purified NisP from the batch shown in (C). (E) Activity test of NisP-8H from
E. coli Rosetta Blue DE3 (pETnisP-8H) after separation by SDS-PAGE. L. lactis NZ9000 (pNZnisA-E3 pIL3BTC) was used both as producer and as sensitive strain.
soluble truncated NisP variants, with or without a tag attached
to the C-terminus of the protein. Additionally, the size of the
inhibition halo measured is larger in the samples activated with
the soluble protease present in the supernatants of these three
engineered strains compared to the samples activated with the
supernatant of L. lactis NZ9000 (pNGnisTP), which produces as
a major product wild-type cell-anchored NisP. This indicates that
the amount of truncated NisP in the supernatants is higher than
the amount of wild-type NisP exposed by the cells. These results
demonstrate that the engineered NisP variants containing only
the protease domain can be recovered from the supernatants.
It also shows that C-terminally tagged NisP retains good
activity.
The truncated NisP variants were also cloned in an E. coli
expression vector, rendering pET28-NisP-8H, pET28-NisP-8K,
and pET28-NisP-sol. The cell pellet obtained after induction of
E. coli Rosetta Blue DE3 transformed with these vectors was
disrupted using glass beads and used in an antimicrobial assay
to activate prenisin. It was possible to activate prenisin using this
fraction, showing the ability of E. coli to produce active truncated
NisP (Figure 2B). Moreover, the supernatants of the induced
cultures were also able to activate prenisin whereas the control
did not.
Purification of NisP and Optimization of
Cleavage Conditions
The strains L. lactis NZ9000 (pNZnisP-8H) and NZ9000
(pNZnisP-8K) were induced and the production of protease
was monitored by SDS-PAGE of the diverse fractions collected
during the purification by either affinity chromatography or
cation exchange chromatography, respectively. We could clearly
detect a highly pure band of approximately 42 kDa, which is
the expected size after removal of the signal peptide during
production (Figure 2C) with an average yield of 1 mg/L. The
protease activity of each fraction was monitored by activation of
prenisin (Figure 2D). Surprisingly, even in fractions for which
the sensitivity of Coomassie blue staining was too low to detect
the protease, activity could still be detected. Similarly, after
induction of E. coli Rosetta Blue DE3 (pET28-NisP-8H) or (pET-
NisP-8K) a protein of approximately 42 kDa was detected in the
supernatants by SDS-PAGE. The gel was covered with a prenisin
producing L. lactis strain demonstrating that this protein could
activate prenisin and create an inhibition zone (Figure 2E).
The activity of NisP on wild-type prenisin was tested in
different buffers based on Tris, HEPES or MES with or without
calcium andmagnesium andmonitored byHPLC.We conducted
the experiments in duplicate at 30 and 37◦C. We found that the
Frontiers in Microbiology | www.frontiersin.org 6 February 2018 | Volume 9 | Article 160
Montalbán-López et al. Specificity of NisP
cleavage in 100mM tris buffer pH 6.0 supplemented with 5mM
CaCl2 at 37◦C was the optimal buffer for the reaction, although
the protease was still reasonably active in the other conditions
(data not shown).
Prenisin Specific Cleavage Using Specific
Proteases in Culture Conditions
To further compare the versatility of NisP in culture conditions
with various proteases frequently used in biotechnology, we
mutated the last four amino acids in the leader peptide (P4-P1)
of nisin (i.e., ASPR) to insert a factor Xa (IEGR) or a thrombin
(AVPR) cleavage site. We also mutated the arginine in position
P1 of the leader peptide into glutamic acid, creating a cleavage
site for the endoprotease Glu-C. Additionally, the proposed self-
cleavage sequence of NisP (VSLR) (Figure 1, van der Meer et al.,
1993) was used to replace the ASPR sequence at the end of the
nisin leader peptide. The supernatants of the prenisin producer
strains containing these mutations were placed in a well on the
agar plate and the specific proteases were added. The cleavage was
evaluated by activity against NZ9000 (pIL253 pNZ8048), which
is resistant to the erythromycin and chloramphenicol present in
the supernatants of the substrate producer strains but sensitive to
nisin. In these conditions, except for Factor Xa, all the proteases
tested (thrombin, NisP and endoprotease Glu-C) were active
(Figure 3).
Specificity of NisP
We designed a set of nisin mutants to investigate the specificity
of NisP (Figure 4). For all these mutants, supernatants were
collected after induction and divided into three fractions. NisP
was added to two of these fractions, one maintaining the pH
of the culture (4.5–5.0) and the other fraction was adjusted to
pH 6.0. The third fraction was used as an untreated control.
After cleavage, the masses of the peptides were monitored by
MALDI-TOF (Table 2).
Lanthionine Ring-Impaired Nisin Mutants
We designed variants of nisin containing only the first ring
(nisin-CAAAA), lacking the first ring (nisin-C7A) and lacking
all the rings (nisin-Cys-less). In order to discard an abnormal
ring formation between Cys11 and an N-terminal dehydrated
residue other than Thr8 in the mutant nisin-C7A, we designed
the mutant nisin-ringA-less, where the first dehydratable residue
is Thr8 and therefore we abolish the possibility of any aberrant
ring formation. Additionally, we mutated the residues P4 to P1
in the leader peptide of nisin to create a VSLR cleavage sequence
in nisin, nisin-CAAAA, nisin-C7A, nisin-ringA-less and nisin-
Cys-less. We observed that wild-type nisin was fully cleaved,
independently of the cleavage sequence at the end of the leader
peptide being ASPR or VSLR. In the other cases, although most
of the cleavage took place in the right position, we were able
to detect masses corresponding to aberrant cleavage by NisP
(Table 2).
The mutant lacking all the cysteines (nisin-Cys-less) was
produced in a very low amount, irrespectively of the cleavage
site present. After the cleavage of nisin-Cys-less, diverse peaks
with a mass corresponding to the cleaved and dehydrated peptide
FIGURE 3 | Activity of the proteases in crude supernatants. Antimicrobial
assay against L. lactis NZ9000 (pIL253 pNZ8048) using different proteases.
Each protease (1 µl) was mixed with supernatant containing 50 µl of its
corresponding prenisin variant. Activity observed results from protease activity
on the substrate releasing active nisin. + indicates a positive control of 50 µl
nisin 10 ng/µl. − indicates a negative control of untreated prenisin.
Supernatants of induced L. lactis NZ9000 (pIL3BTC pNZE3nis-V8) (Glu-C),
NZ9000 (pIL3BTC pNZE3nis-Thr) (Thrombin), NZ9000 (pIL3BTC
pNZE3nisA-ASPR) (NisP-8H ASPR), NZ9000 (pIL3BTC pNZE3nisA-VSLR)
(NisP-8H VSLR), NZ9000 (pIL3BTC pNZE3nis-Fx) (Factor Xa) were mixed with
1 µl of the specific protease.
were detected with a small fraction of incorrectly processed nisin
containing additional residues from the leader peptide (Table 2).
Similarly, in the mutants nisin-CAAAA, nisin-C7A and nisin-
ringA-less, small peaks corresponding to peptides cleaved at
abnormal P1 or P2 positions in the leader peptide were also
observed (Table 2). In the mutants nisin-C7A and nisin-ringA-
less, a small fraction of nisin lacking the first amino acid(s) was
also identified, suggesting cleavage at alternative positions.
Cleavage Site Mutants
Various amino acid residues were replaced at the N-terminus
of the nisin core peptide (positions P1′ and P2′) to investigate
the influence of these residues on the cleavage by NisP. We
engineered positive and negative charges (nisin I1K, nisin
T2K, and nisin I1D), a bulky amino acid (nisin I1W) and
a hydrophobic amino acid in the second position of nisin
core peptide replacing the dehydrobutyrine residue (nisin T2V)
(Table 2). In all P1′ and P2′ mutants, we could detect inhibition
of growth of sensor bacteria after activation with NisP. This
indicates that these positions can tolerate a large variety of amino
acids of very different nature and can still be cut by the specific
protease and retain antimicrobial activity. It was possible to
detect a small fraction of uncleaved peptide after the incubation
of the mutant nisin I1D with the protease, which indicates
reduced cleavage efficiency. The mutant nisin I1K rendered a
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FIGURE 4 | Schematic representation of the cleavage of nisin mutants using NisP-8H. Single mutants are indicated with one letter above wild-type nisin sequence.
Mutants with several amino acid replacements are depicted in bold letters under wild-type nisin sequence. Lanthione rings are represented as a continuous line
connecting Ser or Thr to Cys. The * indicates that this result was also obtained using the same variant with a VSLR cleavages site instead of the wild type ASPR site.
small fraction of mature nisin with a mass difference consistent
with the presence of Arg P1 in the mature peptide, indicating that
the peptide is incorrectly cleaved behind ASP.
Additionally, we tested the efficiency of NisP to cleave other
protease recognition sequences, namely Factor Xa, thrombin,
endoprotease Glu-C, and enterokinase (DDDK and DDDDK
sequences) (Table 2). NisP was able to cleave when a factor Xa
or thrombin site was present. Surprisingly, the nisin mutant with
a glutamic acid in the P1 position of the leader peptide (nisin
V8) was cleaved, although only partially since uncut peptide was
still visible after the experiment. The final amount of undigested
peptide in case of the mutant nisin V8 was higher when the
cleavage was performed at pH 6. The enterokinase sequences
DDDK or DDDDK were not cleaved by NisP in the conditions
tested. Noticeably, no unspecific cleavage in the core peptide of
any of the tested mutants was observed in the conditions tested.
Nisin Mutants in the (D)FNLD Box
Previously reported single alanine replacements of the
characteristic DFNLD motif of type I lantibiotics leader
peptide were studied (Plat et al., 2011). In all cases, cleavage was
taking place normally as shown by mass-spectrometry (Table 2)
and antimicrobial assays (data not shown) were consistent with
previous reports (Plat et al., 2011).
Cleavage of Different Lantibiotic
Substrates
The substrate tolerance of soluble NisP was tested using a set
of different lantibiotics. These were produced using the nisin
modification machinery encoded in NZ9000 (pIL3BTC pNZE3-
mutant) and purified by cationic exchange chromatography. For
this purpose, NZ9000 (pNZ-nisP-8H) was used as a sensor strain
and tested using gallidermin (van Heel et al., 2013) and two
lantibiotics detected in the genome of Streptococcus pneumoniae,
PneA1 and PneA2 encoded in the genes spr1765 and spr1766,
respectively, which were heterologously expressed in L. lactis
fused to the nisin leader peptide (Majchrzykiewicz et al., 2010)
(Figure 5). We could clearly determine that in the absence of
NisP, none of the prelantibiotics tested, not even prenisin, was
active against the sensor strain (data not shown). The activity was
restored when a strain producing soluble NisP was employed.
We could also notice that the NisP producing strain showed
increased sensitivity to nisin (data not shown).
Kinetic Characterization of NisP
The substrate specificity and kinetic parameters of engineered
soluble NisPwere investigated by usingWTprenisin (ASPR), nis-
Peng (VSLR), nis-Thrombin (AVPR), and nis-Factor Xa (IEGR)
as substrates. The Km and Vmax values were determined using
Lineweaver–Burk plots (Figure 6). When wild-type prenisin was
used as substrate, NisP exhibited the highest catalytic efficiency
(Kcat/Km = 1.71 × 106 M−1s−1) and affinity (Km = 0.73µM).
In comparison with wild-type prenisin (ASPR), Nis-Peng (VSLR)
showed a slightly increasedKm value, an identicalKcat value and a
comparable Kcat/Km values (Table 3). For nis-Thrombin (AVPR)
and nis-Factor Xa (IEGR), the 5–6-fold decrease in Kcat/Km was
ascribed to a 10–11-fold increase inKm and 2-fold increase inKcat
compared with that of wild-type prenisin (Table 3). In summary,
soluble NisP displayed the highest catalytic efficiency to wild-
type prenisin (ASPR), followed by Nis-peng (VSLR). A 5–6-
fold decreased catalytic efficiency was observed when Thrombin
(AVPR) and Factor Xa (IEGR) cleavage sites were engineered.
DISCUSSION
Active Soluble NisP Can Be Produced and
Purified
During the production of nisin, the protease NisP is exported
and anchored to the cell wall in a sortase-mediated manner. In
previous attempts to characterize the specificity of NisP, the in
vivo cleavage was based on the detection of the antimicrobial
activity and the detection of mature lantibiotic compared to that
of the prelantibiotic (van der Meer et al., 1994). The activity
in vitro could be confirmed using membrane preparations of
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TABLE 2 | Cleavage of nisin mutants using NisP on crude supernatants of the producer strain directly after fermentation or with the pH adjusted to 6.0.
L. lactis NZ9000 (pIL3BTC) Expected Measured Dehydrations
−NisP +NisP −NisP +NisP +NisP pH 6.0
pNZnisA-E3 5686.4 3354.2 5689.9 (+4.5) 3357.8 (+3.6) 3353.8 (−0.4) 8
3372.2 3372.8 (+0.6) 3370.3 (−1.9) 7
3390.2 3388.0 (−2.2) 3387.9 (−2.2) 6
pNZnisAC7A-ASPR 5654.3 3322.1 5663.9 (+9.6) 3322.7 (+0.6) 8
3240.1 3340.0 (−0.1) 7
3358.1 3357.3 (−0.8) 6
3376.1 3374.9 (−1.2) 5
3476.7 3478.8 (+2.1) 8 (+R)
3494.7 3493.8 (−0.9) 7 (+R)
3512.7 3512.2 (−0.5) 6 (+R)
3208.9 3208.8 (−0.1) 8 (−I)
3226.9 3225.5 (−1.4) 7 (−I)
3244.9 3241.9 (−3.0) 6 (−I)
pNZE3nisA-ringAless-ASPR 5669.3 3337.1 5679.3 (+10.0) 3338.8 (+1.7) 3338.8 (+1.7) 4
3355.1 3357.9 (+2.8) 3357.1 (+2.0) 3
3142.8 3141.2 (−0.6) 3142.0 (−0.8) 3-IV
pNZE3nisA-CAAAA-ASPR 5540.1 3207.9 3207.8 (−0.1) 3210.3 (+2.4) 9
5558.1 3225.9 5556.9 (−1.2) 3224.1 (−1.8) 3227.3 (+1.4) 8
3243.9 3239.9 (−4.0) 3241.6 (−2.3) 7
pNZE3nisA-Cysless-ASPR 5526.1 3175.9 5528.0 (+1.9) 3175.9 (0) 3175.2 (−0.7) 9
3193.9 3191.7 (−2.2) 3189.9 (−4.0) 8
3332.1 3330.9 (−1.2) 9 (+R)
pNZE3nisA-VSLR 5730.4 3354.2 5728.6 (−1.8) 3353.0 (−1.2) 3353.7 (−0.5) 8
3372.2 3368.9 (−3.3) 3366.8 (−5.4) 7
3390.2 3385.9 (−4.3) 3390.9 (+0.7) 6
pNZE3nisA-C7A-VSLR 3322.1 3322.1 (0) 3322.9 (+0.8) 8
5716.4 3340.1 5722.6 (+6.2) 3337.2 (−2.9) 7
3478.3 3478.3 (0) 3479.1 (+0.8) 8 (+R)
3496.3 3493.9 (−2.4) 3495.2 (−1.1) 7 (+R)
3591.4 3590.2 (−1.2) 8 (+LR)
3609.4 3608.6 (−0.8) 7 (+LR)
pNZE3nisA-ringAless-VSLR 5711.9 3337.1 5717.9 (+6.0) 3333.5 (−3.6) 3343.9 (+6.8) 4
3223.9 3231.1 (+7.2) 3230.8 (+6.9) 4 (−I)
pNZE3nisA-CAAAA-VSLR 5602.2 3207.9 5596.2 (−6.0) 3207.3 (−0.6) 3207.8 (−0.1) 8
3225.9 3223.4 (−2.5) 3223.9 (0) 7
3243.9 3239.9 (−4.0) 6
pNZE3nisA-Cysless-VSLR 5552.1 3175.9 3177.8 (+1.9) 3166.7 (−9.2) 9
5588.1 5583.6 (−4.5) 7
3366.8 3361.1 (−5.7) 3365.5 (−1.3) 7 (+R)
3445.2 3444.2 (−1.3) 8 (+VR)
3649.4 3650.9 (+1.5) 3655.5 (+6.1) 7 (+VSLR)
pNZE3nisA-I1K 5737.4 3369.2 5741.6 (+4.2) 3369.9 (+0.7) 3369.6 (+0.4) 6
(Continued)
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TABLE 2 | Continued
L. lactis NZ9000 (pIL3BTC) Expected Measured Dehydrations
−NisP +NisP −NisP +NisP +NisP pH 6.0
5755.4 3387.2 5764.7 (+9.3) 3387.6 (+0.4) 3385.9 (−1.3) 5
3405.2 3404.8 (−0.4) 3403.6 (−1.6) 4
3525.4 3522.1 (−3.3) 8 (+R)
pNZE3nisA-T2K 5729.9 3373.2 3373.0 (−0.2) 7
5747.9 3391.2 5746.2 (−1.7) 3396.4 (+5.2) 3391.0 (−0.2) 6
pNZE3-nisA-T2V 5702.4 3370.2 3370.1 (−0.1) 3770.0 (−0.2) 7
5720.4 3388.2 3387.3 (−0.9) 3388.3 (+0.1) 6
5738.4 3406.2 3404.5 (−1.7) 3405.6 (−0.6) 5
5756.4 5756.4 (0) 4
5774.4 5781.7 (+7.3) 3
pNZE3-nisA-I1D 5706.3 3374.1 3373.4 (−0.7) 3373.7 (−0.4) 7
5724.3 3392.1 3391.2 (−0.9) 3391.7 (−0.4) 6
5742.3 3410.1 5746.6 (+4.3) 3407.7 (−2.4) 5
pNZE3-nisA-I1W 5803.4 3427.1 5808.5 (+4.1) 3425.8 (−1.3) 3424.7 (+0.6) 8
5821.4 3445.1 5820.9 (−0.5) 3444.1 (−1.4) 3443.9 (−1.2) 7
5839.4 3463.1 3460.9 (−2.2) 3464.2 (+1.1) 6
5857.4 5855.3 (−2.1) 5
pNZE3-nisA-V8 5636.3 3331.1 5646.4 (+10.1) 3331.3 (+0.2) 3334.3 (+3.2) 8
3349.1 3348.0 (−1.1) 3353.4 (+4.3) 7
pNZE3-nisA-Thr 5675.4 3331.1 5685.4 (+10.0) 3330.5 (−0.6) 3326.9 (−4.2) 8
3349.1 3350.0 (+0.9) 3350.1 (+1.0) 7
pNZE3-nisA-FX 5707.4 3331.1 5709.5 (+2.1) 3334.7 (+3.6) 3332.9 (+1.8) 8
5725.4 5727.6 (+2.2) 7
pNZE3nisA-DDDK 5748.3 3354.2 5744.9 (−3.4) 5743.2 (−5.1) 8
5766.3 5763.2 (−3.1) 7
pNZE3-DDDDK 5806.3 3354.2 5804.1 (−2.2) 5812.3 (+6.0) 8
5824.3 5824.6 (+0.3) 7
pNZE3-AFNLD 5642.4 3354.2 5643.4 (+1.0) 3355.1 (+0.9) 8
3372.2 3378.8 (+6.6) 3371.8 (−0.4) 7
pNZE3-DANLD 3354.2 3353.0 (−1.2) 3350.7 (−3.5) 8
5628.3 3372.2 5629.9 (+1.6) 3370.1 (−2.1) 3367.8 (−4.4) 7
3390.2 3386.1 (−4.1) 3384.3 (−5.9) 6
3408.2 3402.2 (−6.0) 3400.5 (−7.7) 5
pNZE3-DFALD 5643.4 3354.2 5647.8 (+4.4) 3351.1 (−3.1) 3350.9 (−3.3) 8
3372.2 3368.0 (−4.2) 3371.0 (−1.2) 7
3390.2 3390.8 (+0.6) 3394.2 (+4.0) 6
pNZE3-DFNAD 5644.3 3354.2 5652.9 (+8.6) 3357.3 (+3.1) 8
3372.2 3370.1 (−2.1) 3374.3 (+2.1) 7
3390.2 3387.3 (−2.9) 6
(Continued)
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TABLE 2 | Continued
L. lactis NZ9000 (pIL3BTC) Expected Measured Dehydrations
−NisP +NisP −NisP +NisP +NisP pH 6.0
pNZE3-DFNLA 5642.4 3354.2 3357.7 (+3.5) 3357.5 (+3.3) 8
5660.4 3372.2 5656.0 (−4.4) 3371.9 (−0.3) 3371.2 (+1.0) 7
3390.2 3386.8 (−3.4) 6
pNZE-nis 1(23-34) 2139.0 2138.5 (−0.5) n.d. 5
4489.9 2157.0 4485.8 (−4.1) 2154.6 (−2.4) 4
2175.0 2170.7 (−4.3) 3
−, not addition of NisP; + addition of NisP; n.d., not determined.
The mass difference between the expected and the measured masses is displayed in brackets for each one of the possible dehydration statuses considered. In the case of misscleavage,
the additional or lacking amino acids are displayed in brackets in the dehydration column together with the number of dehydroamino acids.
FIGURE 5 | Antimicrobial activity of purified modified lantibiotics gallidermin,
1215 and 1268 against L. lactis NZ9000 (pNZnisP-8H). (1) Commercial nisin;
(2) elution buffer used during the purification, (3) purified prenisin; (4) pre-1268;
(5) pre-1215; (6) pregallidermin.
cells expressing NisP bound to the cell wall, which limited the
assays. Therefore, we engineered a soluble NisP variant that could
facilitate this task. Our initial hypothesis was that the removal
of the sortase recognition sequence in NisP would abolish the
binding, thus allowing for the purification of unbound protease
in the supernatants (Figure 1). This approach failed to produce
soluble NisP, maybe because NisP cannot fold properly or its
solubility is reduced. Therefore, a second set of NisP mutants,
trimmed at the C-terminus to remove the cell wall spanning
helix, were designed. In this case, it was possible to produce
detectable amounts of active NisP with the expected size in the
supernatants. The activation of prenisin is unambiguously due
to the action of this protease, since the strain with the empty
vector was not able to activate prenisin. We also show that the
purified protein could activate prenisin following SDS-PAGE
electrophoresis, producing an inhibition halo around the band
of the purified protease. These active NisP variants leave the
subtilisin-like serine protease domain intact, and are more
similar in size to other LanP-like proteases, which are naturally
produced as soluble forms (EpiP, Geissler et al., 1996 or PepP,
Meyer et al., 1995) or have been heterologously produced as
soluble proteases (ElxP, Velásquez et al., 2011). Notably, E. coli
was also able to produce mature NisP with the expected size
in the supernatants (data not shown). This indicates that the
secretion signal is correctly processed in E. coli and that the self-
activation of NisP can happen. In previous reported attempts
to express the full length NisP in E. coli, no detection of the
protease by Coomassie staining was possible. However, isotope-
labeled methionine showed the production of a processed NisP
with a size consistent with the removal of the signal sequence
(van der Meer et al., 1993), as was observed in our study. This cell
wall attached NisP could activate prenisin when cell extracts of
induced E. coliwere used (van derMeer et al., 1993). Importantly,
the activity of NisP was not abolished by the addition of a
C-terminal poly-histidine tag or a poly-lysine tag.
NisP Tolerates Mutations at the
N-Terminus of Mature Nisin
A homology modeling study on NisP based on the comparison
with other proteases from the same family predicted an active site
with a binding pocket that could fit 6 amino acids (P4, P3, P2, P1,
P1′, and P2′) (Siezen et al., 1995). It predicts a strong interaction
between the arginine in the position P1 with the protease
mediated by electrostatic interactions with two aspartates in the
enzyme that limits the amino acids in the positions P1′ and P2′ to
be small hydrophobic amino acids (Siezen et al., 1995).
The presence of amino acids of diverse nature in the positions
P1′ and P2′ of nisin shows that these residues can be mutated
without altering the cleavage by NisP. It was anticipated that the
binding of dehydrobutyrine in position P2′ was less important
than the interaction of Ile in position P1′ with a hydrophobic
groove in NisP (Siezen et al., 1995). Some mutants like I1W were
previously shown to be cut by NisP using only the antimicrobial
activity as evidence (Kuipers et al., 1995). Here we show that
it is fully processed under the experimental conditions used.
We could observe that an additional positive charge in the
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FIGURE 6 | NisP kinetic parameters determination using Lineweaver–Burk plot. The substrate concentrations ranged between 1 and 25µM.
TABLE 3 | Kinetic characterization of the cleavage of several nisin leader peptide
mutants.






WT Prenisin (ASPR) 0.73 ± 0.08 1.79 ± 0.10 1.25 ± 0.07 1.71 × 106
Nis-Peng (VSLR) 0.95 ± 0.08 1.79 ± 0.17 1.25 ± 0.11 1.32 × 106
Thombin (AVPR) 7.83 ± 0.27 3.39 ± 0.20 2.37 ± 0.14 3.03 × 105
Factor Xa (IEGR) 7.81 ± 0.01 3.32 ± 0.10 2.33 ± 0.07 2.98 × 105
Data indicate the mean value ± standard deviation.
mutant I1K produced a small additional peak detected by mass-
spectrometry consistent with a cleavage between positions P2 and
P1, suggesting that the accumulation of positive charges favors a
non-specific cleavage by NisP. Bulky or charged amino acids are
well tolerated and the dehydrobutyrine in the second position, or
a previously engineered dehydroalanine (Kuipers et al., 1995), are
not the requirement for cleavage (Siezen et al., 1995).
Lanthionine Rings in Nisin Are Not
Essential for Cleavage by NisP
Additional studies have suggested the requirement of lanthionine
rings as a prerequisite for the substrate recognition (Kuipers et al.,
2004). We engineered various mutants with altered lanthionine
rings. NisP is supposed to cut in the VSLR+QP sequence in
its N-terminus (van der Meer et al., 1993) and VSVR+S at
the C-terminus (Xu et al., 2014), which lack lanthionine rings.
Therefore, we hypothesize that a higher tolerance could be
expected for mutants containing the engineered VSLR site in
the leader peptide. Thus, we engineered in all the mutants
with modified lanthionine ring topology the self-activation site
proposed for NisP, the VSLR cleavage sequence. In previous
work, a nisin mutant (A-4V,P-2L,I1Q,T2P, positions P4, P2,
P1′ and P2′ according to Schechter-Berger nomenclature),
containing the whole self-cleavage site of NisP was previously
reported (van der Meer et al., 1993; Plat et al., 2011). We show
here that VSLR+IT is also cleaved by NisP. The cleavage pattern
observed in the mutants with different number of rings shows
that the presence of lanthionine is not essential for the cleavage,
since nisin Cys-less seems to be cleaved and so is nisin CAAAA.
A similar situation was observed with the cleavage in vitro of
unmodified pre-epilancin 15X and unmodified pre-epidermin
with the specific proteases ElxP and EpiP, respectively (Geissler
et al., 1996; Velásquez et al., 2011). This is in disagreement
with previous work using whole cells expressing cell-attached
NisP that suggests the requirement of lanthionine rings for the
cleavage reaction (Kuipers et al., 2004). This discordance can be
due to the amount of NisP expressed at the cell surface which
could be too small compared to the addition of purified NisP,
the additional replacements in nisin (S-6P, P-2L, positions P6 and
P2, respectively) and/or the shorter incubation time used. It has
been already shown that the binding affinity can be much higher
for the fully modified prelantibiotic than for the unmodified one
(Geissler et al., 1996; Lagedroste et al., 2017). Our results also
indicate that although the lanthionine rings are not essential
for the cleavage, they might favor the correct interaction with
the protease and positioning of the substrate in the active site
since small amounts of prenisin with either additional residues
of the leader peptide or lacking some amino acids of the
core peptide were visible, indicating occasional misprocessing.
NisP production involves self-activation after the N-terminal
signal peptide and cleavage at the C-terminus for optimal
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nisin production. Thus the promiscuity demonstrated in this
study is also related to NisP expression itself (which recognizes
different (auto-)processing sites). This can be exploited for
specific peptide cleavage at various slightly different sites, when
producing variant lantibiotics behind the nisin leader peptide
(Supplementary Figure 1).
NisP Cleaves in All Tested Protease Sites,
Except in the Two Enterokinase Sites
Asmentioned before, the active site of NisP interacts with the last
4 residues of the leader peptide (Siezen et al., 1995). We modified
these last positions in the leader peptide of nisin generating a set
of diverse protease substrates. In such a way, we could investigate
the specificity of NisP and simultaneously compare NisP with
other proteases for the cleavage of the leader peptide in molecules
modified using nisin biosynthesis machinery (vide infra).
The diverse protease sites engineered in the leader peptide
prove that, except for the two enterokinase sites, all the other
cleavage sequences tested could be cleaved by NisP, albeit with
different efficiencies. Our Kcat/Km obtained for wild-type nisin is
in line with previous results in literature, even though a different
buffer is used (Lagedroste et al., 2017). The largest differences are
noticed in the kinetic parameters of nis-Thrombin and nis-Factor
Xa, with a 5–6-fold decrease in the catalytic efficiency (Table 3).
Although the cleavage efficiency in these cases is reduced, this can
be counteracted using prolonged incubation times or a higher
enzyme dose, to yield full cleavage (data not shown). It is not
surprising that the very similar thrombin site can be cleaved
(AVPR vs. ASPR in the wild-type) although the reduction in
the catalytic efficiency points at the favored cleavage with a
hydrophilic residue in the P3 position that can interact with
the solvent out of the protease active site (Siezen et al., 1995).
The replacement of ASPR with the factor Xa cleavage site IEGR
introduces additional changes and a negatively charged residue,
but is still rather efficiently cleaved by NisP. The presence of
negative residues in position P3 is common in other type I
lantibiotics processed by a LanP enzyme such as gallidermin or
epidermin. In contrast, the mutant A-4D (van der Meer et al.,
1994) is not fully cleaved. The predicted interaction partner in
the enzyme is a small hydrophobic pocket and therefore the
mutation A-4D could not fit well into this cleft (Siezen et al.,
1995). Additionally, a weak hydrogen bond interaction between
Ser P3 and NisP was modeled, whereas in EpiP the presence of
lysine residues around the catalytic site could favor a stronger
interaction with the negative charge in epidermin leader peptide
(Siezen et al., 1995). Our results support the idea that a small
hydrophobic amino acid in the P4 position and a polar or charged
amino acid in the P3 position may be important for the correct
positioning of the leader peptide into the active site of NisP.
The highly conserved proline in the P2 position in the
leader peptide of type I lantibiotics could play an important
role in determining the local structure of the leader peptide
and facilitating the access of the protease active site to cleave
the mature prelantibiotic. It is also related to production levels
and transport (Plat et al., 2017). Our data and the self-cleavage
sequences in NisP and several other Pro mutants in the position
P2 (van der Meer et al., 1994; Kuipers et al., 2004; Plat et al., 2011;
Xu et al., 2014) clearly shows that proline is not essential for the
cleavage (Figure 1B).
The highly conserved arginine in the P1 position establishes
a strong ionic interaction with aspartate residues in the model
structure of NisP (Siezen et al., 1995). This position shows certain
flexibility, although the replacements R-1Q, which is present
in other type I lantibiotics such as subtilin, Pep5 or epilancin
15X, and the mutation R-1E present in the mutant nisin V8,
dramatically reduces the cleavage efficiency (van der Meer et al.,
1994 and this work).
Single Alanine Mutations in the (D)FNLD
Box Do Not Hamper Cleavage by NisP
The (D)FNLD box in lantibiotic leader peptides has been shown
to be essential for the optimal interaction with the modification
enzymes in nisin biosynthesis machinery and other type I
lantibiotics (Lubelski et al., 2009; Khusainov et al., 2011, 2013;
Plat et al., 2011, 2013; Knerr and van der Donk, 2012; Abts et al.,
2013). Previous works reported the impact of various mutations
in this region on the modification extent of nisin monitored by
mass-spectrometry and activity tests. However, the activity was
measured after activation with trypsin (Khusainov et al., 2011,
2013; Plat et al., 2011). We considered this DFNLD motif as a
possible recognition sequence also for the protease NisP. This was
previously considered in the homology modeling study in view
on unaligned fragments of NisP that were considered important
for the binding to the substrate prenisin (Siezen et al., 1995). All
the single alanine replacements we tested as substrate for NisP
could still be cleaved correctly. This suggests that either this is not
a recognition site for NisP or that single alaninemutations are not
enough to disrupt the interaction. Similarly, replacements in the
region between the FNLD box and the ASPR cleavage sequence
of the leader had no great impact on the production of nisin, as
was published before (van der Meer et al., 1994).
NisP as a Tool to Release Diverse
Lanthionine-Containing Peptides
The plug-and-play production system for lantibiotics developed
in the last years constitutes a robust platform for the production
of diverse lanthionine-containing peptides (Rink et al., 2005;
Majchrzykiewicz et al., 2010; van Heel et al., 2013, 2016).
Moreover, prelantibiotics have no biological activity and higher
yields can be achieved (Valsesia et al., 2007). Thus, a leader
peptidase with broad specificity for the peptide moiety behind
the cleavage site is desired. A cheap peptidase capable of working
directly in culture broth is preferred since this can facilitate efforts
during high-throughput screening approaches. NisP fulfills these
two criteria and constitutes a valuable tool for the cleavage of
the leader peptide in the production of lanthionine-stabilized
peptide hormones (Kluskens et al., 2009) as well as fully modified
non-cognate prelantibiotics (Figure 5). The increased sensitivity
compared to the plasmid free strain can be due to stress caused
by the production of the protease (data not shown). The attempts
to express the lantibiotic protease ElxP in the wild-type producer
also caused toxicity issues (Ortega et al., 2014).
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Various proteases are commonly used for the cleavage of
recombinant proteins with an affinity tag attached, such as
TEV protease, enterokinase, Factor Xa, or thrombin. Some
of them cleave at the end of their recognition sequence,
whereas some others cleave in between, therefore adding extra
residues after the cleavage site (i.e., TEV protease). The latter
proteases are disadvantageous for our purposes since they leave
some amino acids behind that cannot be removed. Factor Xa
can tolerate most amino acids behind the cleavage sequence
I(D/E)GR with the exception of lysine and proline. However
it needs very controlled conditions and commonly cleaves
incompletely making its biotechnological application costly.
Thrombin, although it cleaves in the middle of the recognition
sequence, shows some flexibility in the residues behind
the cleavage site and tolerates different hydrophobic amino
acids.
We tested different proteases and showed that NisP, the
endoprotease Glu-C, thrombin and trypsin are able to cleave
in culture conditions. Factor Xa could not activate prenisin in
these conditions. Trypsin and the endoprotease Glu-C are very
unspecific, since they can cleave behind positive or negative
residues within the propeptide, respectively. This is a limitation
to their applicability in many cases. However, the endoprotease
Glu-C could be suitable in specific cases due to the low abundance
of negative residues in lantibiotics and the pH conditions during
cleavage can favor the cleavage selectivity for either aspartate or
glutamic acid.
CONCLUSIONS
Taken together, the results presented here suggest that the
protease NisP has greater substrate tolerance than previously
anticipated. The exact recognition motif in the leader peptide
of nisin for the binding of NisP is not yet completely resolved,
although our results agree with the predicted ionic interaction
between Arg in position P1 and NisP as a requirement for
efficient cleavage and confirm that the presence of lanthionine
rings is not mandatory for the cleavage. The determination
of the structure of NisP and the kinetics of the cleavage
reaction of the different mutants could surely shed light on
the residues more directly involved in the binding to NisP.
These insights should help to expand the biotechnological
potential of NisP as a general tool for the cleavage of
proteins with and without lanthionine residues. Our results
also show that among all the proteases tested, NisP is the
most suitable and inexpensive candidate for the activation of
diverse lantibiotics or thioether-stabilized peptides produced
with the nisin leader peptide and the modification machinery of
nisin.
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